The U.S. Food and Drug Administration (FDA) announced a nationwide Class II recall affecting 11,960,623 cartons of Rohto cooling eye drops, with broader agency metrics indicating over 12.4 million individual bottles. Initiated by Vietnam-based manufacturer Rohto-Mentholatum, the voluntary enforcement action addresses identified vulnerabilities in manufacturing quality control protocols that undermine product sterility assurances.
Distributed widely across United States retail channels, the affected over-the-counter ophthalmic goods were marketed to alleviate ocular redness, dryness, and visual strain. The recall encompasses eight distinct product lines sold in single configurations and multi-pack units: All-In-One, Max Strength, Max Strength Twin Pack, Optic Glow, Digi Eye, Dry Aid, Dry Aid Twin Pack, and Cool Relief. Expiration parameters for the compromised lots stretch from July 2025 through February 2029.
Regulatory Classification and Operational Scope
Federal health authorities categorized the enforcement initiative as a Class II recall. This designation indicates that utilizing the compromised products may induce temporary or medically reversible adverse health effects, rendering serious physiological consequences unlikely. Nevertheless, the administrative measure highlights systemic vulnerabilities within international supply chains for sterile over-the-counter pharmaceuticals.
Logistically, the withdrawal of millions of units requires immediate supply chain adjustments for distributors and retail operators to quarantine remaining inventory. Affected consumers must verify product packaging against specific lot numbers to prevent further utilization of the unverified merchandise.
Manufacturing Assurance and Compliance
The foundational justification cited by the FDA involves a lack of sterility assurance across the manufacturing batches. In pharmaceutical production, sterility assurance verifies that finished medical goods remain entirely free from potentially harmful microorganisms. Because topical ophthalmic treatments bypass the body’s primary mucosal defenses, microbial contamination introduces direct infection risks that demand rigorous regulatory oversight.
This deficiency reflects operational challenges inherent in maintaining sterile environments during high-volume production cycles. The enforcement report underscores the continuous responsibility manufacturers bear in upholding strict adherence to current good manufacturing practices (cGMP) to protect public health exposure.
